IRF4 in multiple myeloma—biology, disease and therapeutic target

Agnarelli, Alessandro, Chevassut, Timothy and Mancini, Erika (2018) IRF4 in multiple myeloma—biology, disease and therapeutic target. Leukemia Research, 72. pp. 52-58. ISSN 0145-2126

[img] PDF - Accepted Version
Restricted to SRO admin only until 3 August 2019.

Download (944kB)

Abstract

Multiple Myeloma (MM) is an incurable hematologic malignancy characterized by abnormal proliferation of plasma cells. Interferon Regulatory Factor 4 (IRF4), a member of the interferon regulatory family of transcription factors, is central to the genesis of MM. IRF4 is highly expressed in B cells and plasma cells where it plays essential roles in controlling B cell to plasma cell differentiation and immunoglobulin class switching. Overexpression of IRF4 is found in MM patients’ derived cells, often as a result of activating mutations or translocations, where it is required for their survival. In this review, we rst describe the roles fi of IRF4 in B cells and plasma cells and then analyse the subversion of the IRF4 transcriptional network in MM. Moreover, we discuss current therapies for MM as well as direct targeting of IRF4 as a potential new therapeutic strategy.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
School of Life Sciences > Biochemistry
Subjects: R Medicine
R Medicine > RC Internal medicine
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens
Depositing User: Timothy Chevassut
Date Deposited: 10 Aug 2018 16:14
Last Modified: 06 Nov 2018 18:03
URI: http://srodev.sussex.ac.uk/id/eprint/77753

View download statistics for this item

📧 Request an update